miR-492 Promotes Cancer Progression by Targeting GJB4 and Is a Novel Biomarker for Bladder Cancer

This article was published in the following Dove Press journal: OncoTargets and Therapy

Kai Wang
Hang Lü
Hongchen Qu
Qingpeng Xie
Tao Sun
Ou Gan
Bin Hu

Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People’s Republic of China

Background: Bladder cancer is the most common urinary system malignancy in the United States and is characterized by its diverse prognosis and high recurrence rate. However, the molecular mechanisms underlying its progression remain unknown. Accumulating evidence suggests a critical role for miRNAs in bladder cancer progression.

Methods and results: In this study, we found that miR-492 expression levels were significantly higher in bladder cancer tissue and the serum of bladder cancer patients by bioinformatics analysis and a panel of clinical samples. The results of receiver operating characteristic curve analysis suggested the potential diagnostic value of serum miR-492 for bladder cancer. In vitro and in vivo functional assays showed that knockdown of miR-492 suppressed proliferation and metastasis of bladder cancer cells. Gap junction beta-4 protein was predicted to be a direct target of miR-492, which was validated using a luciferase reporter assay. Further cellular functional assays showed that suppression of miR-492 abrogated bladder cancer cell proliferation and metastasis by targeting gap junction beta-4 protein.

Conclusion: miR-492 promotes cancer progression by targeting GJB4 and is a novel biomarker for bladder cancer.

Keywords: miRNAs, miR-492, bladder cancer, GJB4, biomarker

Introduction

Bladder cancer is the most common urinary system malignancy in the United States. Estimated new cases of bladder cancer in male patients are three times more than that of female patients. Clinical outcomes for bladder cancer differ significantly with different clinical and prognostic variables. The five-year relative survival rates for bladder cancer are 96% for carcinoma in situ, 70% for localized, 35% for regional, and 5% for distant. Unfortunately, 40 to 80% of patients with carcinoma in situ will have disease recurrence or progression after standard clinical treatment. Elevation of the overall survival rate of bladder cancer patients requires further elucidation of the molecular mechanisms underlying disease progression and identification of novel diagnostic biomarkers.

MicroRNAs (miRNAs) are small noncoding RNAs that can mediate the degradation of their target messenger RNAs (mRNAs) or inhibit their translation by binding to seed sequences in their 3’-untranslated regions. Multiple studies have reported that aberrant expression of miRNAs correlates closely with disease progression in multiple cancer types. Furthermore, miRNAs are also enriched in...
human body fluids (e.g., blood, saliva, bile). The expression profile of miRNAs in cancer patient blood could reflect the pathological status, which makes miRNAs promising candidates for novel biomarkers in cancer. miR-492 has been reported to promote cancer progression in several cancer types. However, the role of this miRNA in bladder cancer and its potential as a biomarker has not been reported.

In this study, we found that miR-492 was significantly upregulated in bladder cancer tissue and serum from bladder cancer patients using bioinformatics analysis of two different Gene Expression Omnibus (GEO) miRNA microarray datasets. These findings were validated with a panel of clinical samples, suggesting that miR-492 expression is significantly higher in bladder cancer tissue and patient serum than para-cancerous tissues and serum from healthy participants. Receiver operating characteristic (ROC) curve analysis showed the potential diagnostic value of serum miR-492 for bladder cancer. In vitro and in vivo experiments demonstrated that knockdown of miR-492 could suppress proliferation, migration, invasion, and the epithelial-mesenchymal transition, and induce apoptosis in bladder cancer cells by targeting gap junction beta-4 protein (GJB4).

**Materials and Methods**

**Ethics Approval and Consent to Participate**

Animal studies and usage of clinical samples were approved by the ethics committee of the Liaoning Cancer Hospital and Institute (Affiliated Cancer Hospital of China Medical University). All participants received and signed a detailed written informed consent form. Animal handling procedures were performed according to the standards of the local ethics committee.

**Bioinformatics Analysis**

Two publicly available miRNA microarray datasets (GSE40355, 16 bladder cancer tissue samples and eight normal bladder tissue samples; GSE112264, 50 bladder cancer serum samples and 40 normal control serum samples) were downloaded from the public Gene Expression Omnibus database. Differentially expressed miRNAs were analyzed with the R language package edgeR. Heatmaps of the differentially expressed miRNAs were visualized using the R language package pheatmap. The miR-492 expression levels in the two datasets were visualized using GraphPad Prism 7.

**Cell Lines and Cell Culture**

The human bladder cancer cell lines (UM-UC-3 and T24) were purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (SIBCB). Cells were cultured in RPMI-1640 (Gibco, NY, USA) supplemented with 10% fetal bovine serum (Gibco).

**Reverse Transcription Quantitative Polymerase Chain Reaction**

Total RNA from cell lines and ground tissues was isolated with TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions. Serum miRNA was isolated with the Serum (Plasma) miRNA Isolation Kit (Foregene, Chengdu, China) according to the manufacturer’s protocol. The concentration and quality of the isolated RNA were determined using the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, USA). For miR-492 detection, total RNA was converted into cDNA using the miRNA 1st Strand cDNA Synthesis Kit (Vazyme). For GJB4 detection, cDNA was generated from total RNA using the RT SuperMix for qPCR kit (Vazyme). miR-492 and GJB4 expression were measured by qPCR using the SYBR qPCR Master Mix kit (Vazyme). The primer sequences were: Hsa-miR-492 forward, 5′-GGGGTACCCCTGGCTGGAAACAGAGAT-3′; Hsa-miR-492 reverse, 5′-CCCAAGCTTCCCTGC-3′; U6 forward, 5′-CGCTTCGGCA GCACTATAC-3′; U6 reverse, 5′-TTACAGAATTGCGTG TCATC-3′; GJB4 forward, 5′-TCAATGCACCAGCTTAA AAG-3′; GJB4 reverse, 5′-GGGGGA CCTGTTGATCTTA TC-3′; GAPDH forward, 5′-ACAACCTTGGTATCGTG AGG-3′; GAPDH reverse, 5′-GCCATCACGCCACAGTT TC-3′.

**Western Blotting Assay**

Cells and ground tissue were resuspended in RIPA buffer supplemented with protease inhibitor for 20 min on ice. Protein concentration was determined using the bicinchoninic acid protein assay kit (Beyotime, Tianjin, China) according to the manufacturer’s instructions. Total protein (40 μg) from each sample was separated on a polyacrylamide slab gel and transferred to a PVDF membrane (Bio-Rad, CA, USA). Membranes were incubated overnight at 4°C with primary antibody against GJB4 (1:1000, Abcam, Cambridge, UK), β-actin (1:8000, Proteintech, Rosemont, USA). Blots were incubated with horseradish peroxidase-conjugated secondary antibody (1:2000, Proteintech). Protein bands were visualized using the enhanced BeyoECL Plus kit (Beyotime).
Transfection Experiments
Synthetic miR-492 mimics, miRNA mimic negative control, miR-492 inhibitor (shRNA plasmids), negative control RNA inhibitor (shRNA plasmids), GJB4 siRNA, and negative control siRNA were purchased from GenePharma Biotechnology (GenePharma, Shanghai, China). Transfection experiments were performed using Lipofectamine 3000 reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions.

Figure 1 miR-492 is upregulated in bladder cancer tissue and bladder cancer patient serum. (A) Heatmap of differentially expressed miRNAs in the GSE40355 dataset. (B) Heatmap of differentially expressed serum miRNAs in the GSE112264 dataset. (C) miR-492 expression levels in the GSE40355 dataset. (D) miR-492 expression levels in the GSE112264 dataset. (E) miR-492 expression levels in 23 paired bladder cancer and paracancerous tissues by RT-qPCR. (F) miR-492 expression levels in different stage of bladder cancer. (G) Serum miR-492 expression levels in 23 bladder cancer patients and 23 healthy volunteers by RT-qPCR. (H) ROC analysis of the diagnostic value of serum miR-492 for bladder cancer. *p < 0.05, ****p < 0.0001, ns for non significant.

Abbreviation: AUC, area under curve.
Cell Proliferation Assay

The cell proliferation assay was performed using the Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan) and Cell-Light 5-ethyl-2′-deoxyuridine (EdU, Beyotime) DNA cell proliferation assays according to the manufacturers’ protocols. For the EdU assay, nuclei were stained with Hoechst 33342, and the cells were visualized under a fluorescence microscope. Exposure times were 30 sec for visualization of Apollo and 0.180 sec for nuclei.

Flow Cytometric Apoptosis Analysis

For apoptosis analysis, cells were collected after experimental treatment and washed with PBS. The cells were then stained with the FITC/Annexin V Apoptosis Detection Kit I (BD Biosciences, NY, USA) and analyzed by flow cytometry (Thermo Fisher Scientific).

In vitro Migration Assay

For wound healing migration assays, cells with corresponding experimental treatment were cultured in 6-well plates until confluent. A wound was made across the cell monolayer using a pipette tip. The wounded cell monolayer was then cultured in 2.5% serum medium. Photos of the wound were taken at 0 and 18 h using light microscopy.

In vitro Invasion Assay

For invasion assays using Transwells (24-well, 8-μm pore size filters, Costar, NY, USA), 2×10⁴ cells with corresponding experimental treatment in serum- and antibiotic-free medium were added to the upper chambers pre-coated with Matrigel (dilution 1:8, BD Biosciences). The lower chambers were filled with RPMI-1640 containing 10% serum and antibiotics. After co-culture for the indicated times, cells and Matrigel invasion were removed, and cells that invaded the lower surface were fixed with 4% paraformaldehyde. Fixed cells were stained with crystal violet and counted using light microscopy.

Luciferase Reporter Assay

Putative miR-492 targets were predicted using TargetScan (http://targetscan.org/). Based on this analysis, GJB4 was predicted as a potential miR-492 target. The 3′-UTR of GJB4 containing the wild-type or mutant miR-492 binding site was constructed by Genechem Biotechnology (Shanghai, China). A total of 3×10⁴ UM-UC-3 or T24 cells were seeded in triplicate in 24-well plates and co-transfected with the corresponding plasmids and miR-492 mimics. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, USA) according to the manufacturer’s protocol.

Bladder Cancer Xenografts

Subcutaneous tumors were generated in 5-week-old female BALB/c nude mice (Huafukang, Beijing, China). UM-UC-3 cells (8×10⁵) transfected with miR-492 inhibitor or negative control RNA inhibitor were subcutaneously injected in 150 μL PBS into the right axilla area. Tumors were measured once per week using a Vernier caliper. Mice were euthanized four weeks after the inoculation, and the tumors excised and measured. Tumor volume was calculated using the following equation: (L×W²)/2 where L was the length of the long axis, and W was the length of the short axis.

Statistical Analysis

The Student’s t-test was performed using SPSS Statistics 19.0. P-values of <0.05 were considered statistically significant. The receiver operating characteristic curve analysis was performed using GraphPad Prism 7. Statistical charts were generated with GraphPad Prism 7.

Table 1 Clinical Characteristics of 23 Bladder Cancer Patients and Healthy Participants in This Study

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Case Number (Patients/Healthy Participants)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>23/23</td>
<td>100%/100%</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>19/16</td>
<td>83%/70%</td>
</tr>
<tr>
<td>Female</td>
<td>4/7</td>
<td>17%/30%</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>15/3</td>
<td>65%/13%</td>
</tr>
<tr>
<td>&lt;60</td>
<td>8/20</td>
<td>35%/87%</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TaN0M0</td>
<td>5/–</td>
<td>6/–</td>
</tr>
<tr>
<td>T1N0M0</td>
<td>4/–</td>
<td>2/–</td>
</tr>
<tr>
<td>T2N0M0</td>
<td>2/–</td>
<td>1/–</td>
</tr>
<tr>
<td>T3N1M1</td>
<td>1/–</td>
<td></td>
</tr>
<tr>
<td>Histology grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>10/–</td>
<td>43%/–</td>
</tr>
<tr>
<td>High</td>
<td>13/–</td>
<td>57%/–</td>
</tr>
</tbody>
</table>
Figure 2 miR-492 promotes proliferation and inhibits apoptosis of bladder cancer cells. (A) Knockdown of miR-492 expression levels in UM-UC-3 and T24 cells by transfection with miR-492 inhibitor or inhibitor NC. (B) CCK-8 assay for UM-UC-3 or T24 cells transfected with miR-492 inhibitor or inhibitor NC. (C) EdU assay for UM-UC-3 or T24 cells transfected with miR-492 inhibitor or inhibitor NC. (D) Flow cytometric analysis for apoptosis in UM-UC-3 or T24 cells transfected with miR-492 inhibitor or inhibitor NC. **p < 0.01, ***p < 0.001.

Abbreviation: NC, negative control.
Results
miR-492 Expression Is Significantly Upregulated in Bladder Cancer Tissue and Bladder Cancer Patient Serum
We analyzed the data from two independent publicly available GEO microarray datasets (Figure 1A and B). We found that miR-492 was significantly upregulated in bladder cancer tissue and bladder cancer patient serum (Figure 1C and D). We validated these results using a panel of clinical samples (Table 1). Analysis of this panel showed that miR-492 expression levels were higher in bladder cancer tissue and bladder cancer patient serum than in paracancerous tissue or serum from healthy participants (Figure 1E and F). The results of the ROC analysis showed the potential diagnostic value of serum miR-492 levels in bladder cancer (Figure 1G).

Knockdown of miR-492 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer Cells
Based on expression analysis, we investigated the role of miR-492 in bladder cancer progression by suppressing miR-492 expression in UM-UC-3 and T24 cells by transfection of miR-492 inhibitors (Figure 2A). Knockdown of miR-492 expression suppressed proliferation (Figure 2B and C) and induced apoptosis (Figure 2D) of UM-UC-3 and T24 cells. Furthermore, knockdown of miR-492 expression abrogated the growth of UM-UC-3 xenografts (Figure 3A–D).

Figure 3 miR-492 promotes growth of bladder cancer cells in vivo. (A) Surgically excised tumor tissue four weeks after initial implantation. (B) Tumor volumes of surgically excised tumor tissue four weeks after initial implantation. (C) Growth curve of subcutaneously implanted tumors. (D) miR-492 expression in surgically excised tumor tissue by RT-qPCR. *p < 0.05, **p < 0.01.
Abbreviation: NC, negative control.
Knockdown of miR-492 Suppresses Bladder Cancer Cell Metastasis in vitro
We investigated the effect of miR-492 on the metastasis of bladder cancer cells. In vitro migration and invasion assays showed that knockdown of miR-492 suppressed migration and invasion of bladder cancer cells (Figure 4A and B).

GJB4 Is a Direct Target Gene of miR-492 in Bladder Cancer Cells
We predicted potential target genes of miR-492 by bioinformatics analysis and selected GJB4 for further analysis (Figure 5A). Luciferase activity from a reporter plasmid carrying wild-type, but not mutant, GJB4 3'-UTR was significantly decreased by miR-492 overexpression in UM-UC-3 and T24 cells (Figure 5B). Furthermore, miR-492 overexpression reduced GJB4 expression, and miR-492 knockdown increased GJB4 expression in both cell lines at both the mRNA and protein level (Figure 5C and D). These results suggest that GJB4 is a direct target gene for miR-492 in bladder cancer cells.

miR-492 Suppresses Proliferation and Metastasis of Bladder Cancer Cells by Targeting GJB4
To determine whether the functions of miR-492 are achieved by its targeting of GJB4, we decreased miR-492 and GJB4 expression by transfection of an miR-492 inhibitor and GJB4 siRNA, respectively, or corresponding controls (Figure 6A). In vitro functional experiments showed that the inhibitor/siRNA group had a similar phenotype to that of the control group. In contrast, the inhibitor/NC siRNA group displayed decreased proliferation, migration, invasion, and increased apoptosis (Figures 6B–D and 7A, B). These results suggest that miR-492 promoted proliferation and metastasis of bladder cancer cells by targeting GJB4.

Discussion
Though many countries, such as the United States, have developed standard screening, early detection, and clinical therapy for patients with bladder cancer, the prognosis of these patients differs significantly. For patients with local invasion and distant metastasis at the time of diagnosis,
surgery provides limited efficacy. Furthermore, bladder cancer is characterized by a high recurrence rate after surgery. Even for patients with carcinoma in situ, 40 to 80% will have disease recurrence or progression after standard clinical treatment. Therefore, to increase the overall survival rates for bladder cancer patients, further elucidation of the underlying molecular mechanisms is required.

Several studies have reported the tumor-promoting effect of miR-492 in other cancer types. miR-492 promoted prostate cancer growth by repressing SOCS2, hepatoblastoma metastasis via CD44, and breast cancer proliferation by suppressing SOX7. Aberrant miR-492 expression has also been correlated with chemoresistance in cervical and colon cancer. In contrast, circular RNA circ0072309 inhibited proliferation and invasion of breast cancer cells by targeting miR-492. These studies demonstrated the tumor-promoting activity of miR-492. However, the role of miR-492 in bladder cancer was not reported.

In this study, we found that miR-492 was upregulated in both bladder cancer tissue and bladder cancer patient serum by bioinformatics analysis, which was validated in a panel of clinical samples. Considering that miR-492 was enriched in bladder cancer patient serum, we further studied its potential as a diagnostic biomarker for this disease. The results from the ROC analysis showed the potential diagnostic value of serum miR-492 for bladder cancer detection. The results of the functional analysis showed the significant tumor-promoting activity of miR-492 as miR-492 knockdown suppressed proliferation and metastasis of bladder cancer cells. These data suggest that miR-492 may act as a broad-spectrum tumor promoter and serve as a novel target for cancer therapy. The results of this study validated GJB4 as a direct target of miR-492. Further functional analysis showed that miR-492...
Figure 6 miR-492 promotes proliferation and inhibits apoptosis of bladder cancer cells by targeting GJB4. (A) Knockdown of GJB4 expression in UM-UC-3 and T24 cells by GJB4 siRNA. (B) CCK-8 assay of UM-UC-3 and T24 cells transfected with miR-492 inhibitor/GJB4 siRNA or inhibitor/NC siRNA. (C) EdU assay of UM-UC-3 and T24 cells transfected with miR-492 inhibitor/GJB4 siRNA or inhibitor/NC siRNA. (D) Flow cytometric analysis for apoptosis of UM-UC-3 and T24 cells transfected with miR-492 inhibitor/GJB4 siRNA or inhibitor/NC siRNA. **p < 0.01, ***p < 0.001.

Abbreviation: NC, negative control.
suppressed proliferation and metastasis of bladder cancer cells by targeting GJB4. Multiple studies have reported a close correlation between dysregulated gap junction protein family expression and cancer progression.29–33 However, only one study has reported a role for GJB4 in lung cancer progression.34 Our results may provide some useful data for future studies on the GJB4.

In conclusion, our study was the first to report the aberrant expression and tumor-promoting activity of miR-492 via GJB4 in bladder cancer. Our results may provide
evidence for further development of miR-492 as a novel biomarker and therapeutic target for bladder cancer.

Acknowledgment
The study was funded by National Fund of China Foreign Experts Bureau (20172100003).

Author Contributions
KW performed most of the experiment and wrote the paper. HL, HQ, QX, TS, and OG collected clinical samples and performed some of the experiments. BH designed the study, analyzed the data and revised the paper. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


